Investment Rating - The report does not explicitly state an investment rating for the petrochemical industry, but it provides insights into price trends and market conditions that could influence investment decisions. Core Insights - The report highlights that the downstream stocking demand for winter is nearing its end, with polyester filament experiencing slight inventory accumulation [1]. - Domestic key refining project price spread is reported at 2540.74 CNY/ton, with a week-on-week increase of 7.17 CNY/ton (0.28%), while the international price spread is at 1303.62 CNY/ton, showing a decrease of 27.50 CNY/ton (-2.07%) [2][3]. - Brent crude oil's average price for the week ending December 19, 2025, is noted at 60.08 USD/barrel, reflecting a week-on-week decline of 3.10% [2]. Refining Sector Summary - The report discusses geopolitical factors affecting oil prices, including negotiations between Ukraine and the U.S. and sanctions on Venezuelan oil, which have led to fluctuations in international oil prices [2]. - Domestic refined oil prices have slightly decreased, with improvements in price spreads. The average prices for diesel, gasoline, and aviation kerosene are reported as 6625.29 CNY/ton, 7641.71 CNY/ton, and 5800.48 CNY/ton, respectively [15]. - The report notes that the chemical sector has seen a general decline in chemical prices, with some products experiencing smaller declines relative to cost, leading to improved price spreads [2]. Chemical Sector Summary - In the polyester sector, the report indicates that the price of PX and MEG has slightly decreased, while PTA prices remain stable. The overall price trend in the polyester industry is downward due to weak demand and increased production capacity [2]. - The report mentions that the EVA market is seeing price declines as production resumes from maintenance, with the average price reported at 9778.57 CNY/ton [50]. - The report also highlights that the price of pure benzene remains stable, while styrene prices have decreased due to weak cost support, with the average price reported at 6614.29 CNY/ton [50].

Investment Rating - The industry investment rating is "Positive" [2] Core Insights - The European Union announced a comprehensive plan for grid upgrades, expecting to invest €1.2 trillion by 2040, with €730 billion allocated for distribution networks and €240 billion for hydrogen networks. The plan anticipates an average annual investment of €80 billion, compared to the current annual investment of €50-60 billion. This investment will cover power interconnection, energy storage, and hydrogen sectors. The EU aims to reduce industrial electricity prices to enhance the export competitiveness of its industrial products [2][3] Summary by Sections Investment Opportunities - Domestic manufacturers are well-positioned in high-voltage transmission, smart meters, and wind power, with advanced technologies. China's high-voltage technology enables large-scale, long-distance power transmission, effectively addressing energy distribution issues, making it highly competitive in overseas grid construction. The global power grid upgrade cycle is expected to significantly benefit these companies [4] Recommendations - The report suggests focusing on investment opportunities in power equipment exports and recommends companies such as Siyi Electric, Igor, Jinpan Technology, TBEA, China XD Electric, Huaming Equipment, Shunma Power, Mingyang Electric, and Samsung Medical [4]

行业点评：澳洲户储补贴加码，户储渗透率有望大幅提升 [Table_ReportDat] 2025 年 12 月 20 日 证券研究报告 行业研究 [行业Tabl事项e_ReportType] 点评 [Table_StockAndRank] 电力设备与新能源 投资评级 看好 上次评级 看好 胡琎心 电新行业首席分析师 执业编号：S1500525080001 联系电话：010-83326711 邮 箱：hujinxin@cindasc.com 姚云峰 电力设备与新能源行业联系人 联系电话：18840829584 邮 箱：yaoyunfeng@cindasc.com 澳洲储能贡献国内供应商明显增量，需求具备持续性。据 CESA 储能应用分 会数据库统计，2025 年 1-9 月，中国企业在澳大利亚储能市场那些的订单 共计 43.21GWh，占比 20.13%，成为中国企业海外储能订单第二大来源地。 今年 9 月，特斯拉能源亚太区区域总监 Josef Tadich 透露，到 2026 年底， 特斯拉将在澳大利亚投入运营约 4.5GW/12GWh 的构网型储能系统（Grid Forming BESS），并预计这一数字未 ...

Investment Rating - The industry investment rating is "Positive" [2] Core Insights - The report highlights that the express delivery industry is experiencing a structural optimization in peak season, with leading e-commerce express companies increasing their market share [3][4] - In November, the express delivery business volume grew by 5.0% year-on-year, with cumulative physical goods online retail sales reaching 11.82 trillion yuan, a 5.7% increase [4][15] - The report emphasizes the ongoing growth potential in the express delivery sector, driven by the rise of live e-commerce and increasing online shopping penetration [7][40] Summary by Sections Industry Situation - In November, the express delivery industry saw a business volume increase of 5.0% year-on-year, with a cumulative total of 1,807.4 billion packages delivered from January to November, reflecting a 14.9% year-on-year growth [4][15] - The average package value decreased by 12.9% year-on-year to approximately 65.4 yuan [15] Company Performance - In November, the business volume for major companies was as follows: YTO Express at 2.886 billion packages, Shentong Express at 2.502 billion packages, Yunda Express at 2.175 billion packages, and SF Express at 1.534 billion packages [5][28] - SF Express's business volume growth rate was 20.13%, while cumulative growth from January to November was 27.25% [5][28] Market Share - Cumulative market share from January to November showed YTO Express at 15.6%, Shentong Express at 13.1%, Yunda Express at 13.0%, and SF Express at 8.4% [5][29] - SF Express's market share increased by 0.8 percentage points year-on-year [29] Pricing Situation - The average price per package in the express delivery industry increased by 1.9% month-on-month in November, reaching 7.62 yuan, although it was down 8.3% year-on-year [6][26] - SF Express's average price per package was 13.47 yuan in November, reflecting a month-on-month increase of 0.29 yuan [6][29] Investment Recommendations - The report recommends investing in SF Express as a leading comprehensive express logistics company, anticipating a turning point in operations and cash flow [8][41] - It also suggests looking at Zhongtong Express and YTO Express, while keeping an eye on Yunda Express and Shentong Express due to the ongoing recovery in the express delivery sector [8][41]

Investment Rating - The report maintains a "Positive" investment rating for the environmental sector [4]. Core Insights - The environmental sector has shown resilience, with a 0.3% increase in the sector's performance, outperforming the broader market [4][11]. - The report highlights the ongoing expansion of waste-to-energy companies in Southeast Asia, particularly in Vietnam, Thailand, and Indonesia, where waste management issues are significant [5][19][25]. - The Vietnamese government aims to increase waste recycling and processing, with a target of 95% by 2030, while currently, only 10% of waste is incinerated [21][22]. - Thailand's waste management is heavily reliant on landfills, with over 70% of waste sent to landfills, and the government plans to increase waste-to-energy capacity significantly by 2037 [25][26]. - Indonesia faces severe waste management challenges, with only 9-10% of waste processed properly, prompting government initiatives to expedite waste-to-energy project approvals [27][28]. Summary by Sections Market Performance - As of December 19, the environmental sector rose by 0.3%, outperforming the Shanghai Composite Index, which remained flat [4][11]. Industry Dynamics - The report discusses the release of the 2025 energy-saving and carbon reduction technology equipment directory, which includes over 350 technologies aimed at improving energy efficiency [32]. - The report notes the government's push for clean and efficient coal utilization, indicating a shift towards higher value products in the coal industry [33]. Waste-to-Energy Market in Southeast Asia - Vietnam generates significant waste, with 63% currently landfilled and only 10% incinerated. The government has set ambitious waste management goals [19][21]. - Thailand's waste generation is increasing rapidly, with a focus on enhancing waste-to-energy capacity as part of its renewable energy development plan [25][26]. - Indonesia's government is actively working to improve waste management, with plans to streamline project approvals for waste-to-energy facilities [27][28]. Investment Recommendations - The report suggests that the environmental sector, particularly waste management and recycling, is expected to maintain high growth due to government policies and market reforms. Key companies to watch include Huanlan Environment, Xingrong Environment, and Hongcheng Environment [5][51].

Investment Rating - The investment rating for the utility sector is "Positive" [2] Core Insights - In November, the industrial power generation in China increased by 2.7% year-on-year, while natural gas production rose by 5.7% year-on-year [4] - The report indicates a potential for profit improvement and value reassessment in the power sector due to previous supply-demand tensions [4] - The ongoing market reforms in electricity pricing are expected to lead to a slight increase in electricity prices, benefiting power operators [4] Summary by Sections Market Performance - As of December 19, the utility sector declined by 0.6%, underperforming the broader market [11] - The electricity sector fell by 0.66%, while the gas sector saw a slight increase of 0.11% [12] Electricity Industry Data Tracking - The price of thermal coal at Qinhuangdao Port (Q5500) was 711 CNY/ton as of December 19, down 42 CNY/ton week-on-week [20] - Coal inventory at Qinhuangdao Port decreased to 7.28 million tons, a decline of 20,000 tons week-on-week [26] - The average daily coal consumption for inland power plants was 3.758 million tons, down 166,000 tons/day week-on-week [29] Natural Gas Industry Data Tracking - The LNG ex-factory price index in China was 4,075 CNY/ton as of December 18, down 10.91% year-on-year [55] - Domestic natural gas apparent consumption in October was 34.77 billion cubic meters, a decrease of 1.6% year-on-year [4] - In November, LNG imports reached 6.94 million tons, an increase of 12.8% year-on-year [4] Key Industry News - The report highlights that the industrial power generation maintained growth, with November's output at 779.2 billion kWh, a 2.7% increase year-on-year [4] - The natural gas production in November was 21.9 billion cubic meters, reflecting a stable growth trend [4] Investment Recommendations - For the electricity sector, it is suggested to focus on leading coal power companies such as Guodian Power, Huaneng International, and Huadian International [4] - In the natural gas sector, companies with low-cost long-term gas sources and receiving station assets are recommended, such as Xin'ao Co. and Guanghui Energy [4]

Investment Rating - The industry investment rating is "Positive" as the industry index is expected to outperform the benchmark [14] Core Insights - The new standards for clean and efficient coal utilization have been released, marking a shift towards "structural optimization and quality enhancement" in the coal industry [1] - The policy emphasizes the importance of clean and efficient coal utilization as a key direction for high-quality development in the coal industry and a crucial support for achieving carbon peak and carbon neutrality goals [3] - The updated standards expand the coverage to include new areas such as coal-to-natural gas and coal-to-oil, reflecting a shift from mere fuel cleanliness to high-value material utilization [3] - The implementation mechanism has been strengthened, with a clear three-year renovation timeline and elimination mechanism for projects that fail to meet the baseline standards [3] Summary by Sections Policy Changes - The new standards are a systematic upgrade from the previous version, with three core changes: expanded coverage, elevated standard levels, and a hardened implementation mechanism [3] - The benchmark levels are aligned with "domestic and international advanced levels" and the "strictest pollutant emission requirements," ensuring continuous updates in line with national policies [3] Industry Development - The coal industry is undergoing energy-saving and carbon reduction efforts, with increasing constraints on targets [4] - The coal power sector has seen a gradual decrease in average coal consumption per kilowatt-hour over the past several five-year plans, indicating ongoing improvements in carbon emissions [4] Investment Opportunities - Key investment directions include companies involved in flue gas treatment, waste heat recovery, advanced carbon capture technologies, recycling of coal gangue, and carbon emission monitoring [4]

Investment Rating - The investment rating for the airline transportation industry is "Positive" [2][7]. Core Insights - The industry has maintained a high passenger load factor during the off-peak season, with both domestic and international travel thriving. The high load factor and slight recovery in ticket prices suggest a significant improvement in airline unit revenue. The implementation of "anti-involution" measures and the self-regulatory agreement by the China Air Transport Association is expected to reduce malicious low pricing, further supporting ticket price recovery and enhancing airline profitability. Additionally, the decline in oil prices is likely to reduce costs, contributing to further profit growth for airlines. Key airlines to focus on include China Southern Airlines, China Eastern Airlines, Air China, Spring Airlines, and Juneyao Airlines [3][13]. Summary by Sections 1. Investment Recommendations - The industry has seen sustained high passenger load factors since early 2025, with both domestic and international routes performing well. The off-peak season is not as weak as expected, with high load factors and a slight recovery in ticket prices, indicating a potential significant recovery in airline unit revenue. The implementation of self-regulatory measures is expected to mitigate low pricing practices, further supporting ticket price recovery and enhancing airline profitability [3][13]. 2. Off-Peak Passenger Load Factor and Ticket Prices 2.1 Supply and Demand - The capacity growth rate has rebounded, leading to an increase in passenger load factors. In October 2025, the industry’s Available Seat Kilometers (ASK) and Revenue Passenger Kilometers (RPK) increased by 6.2% and 8.9% year-on-year, respectively, with a load factor of 87.4%, up 2.2 percentage points year-on-year [4][15]. 2.2 Ticket Prices - Ticket prices have weakened in December, with the average domestic ticket price at 839 yuan, down 7.0% year-on-year. The average ticket price for domestic routes, including fuel, was 709 yuan, down 6.2% year-on-year [4][23]. 2.3 Oil Prices and Exchange Rates - The average price of aviation fuel has slightly increased in December, with the domestic aviation fuel price at 6045 yuan per ton, up 3.9% year-on-year. The exchange rate of the Chinese yuan has appreciated against the US dollar, with the exchange rate at 7.0602 yuan per dollar as of December 16, 2025, down 1.78% from the end of 2024 [5][37]. 3. Airline Capacity and Load Factors 3.1 Operational Status - In November, most airlines maintained stable capacity growth, with significant increases in international capacity. The passenger load factors for both domestic and international routes have shown year-on-year improvements, significantly increasing compared to 2019 levels [4][43]. 3.2 Fleet Expansion - In November, Air China and China Southern Airlines each added 7 aircraft, marking the highest net increase among the six major airlines. From January to November, China Southern Airlines, Air China, and China Eastern Airlines saw net increases of 47, 26, and 21 aircraft, respectively [4][7].

Core Insights - The report highlights a significant shift in the pharmaceutical and biotechnology industry, moving from a follower to a leader in innovation, particularly in the context of international expansion and high-end product development [3][4] - The overall industry revenue and profit growth are expected to rebound after a period of decline, driven by the recovery of innovative drugs and the CXO sector [3][4] Industry Performance and Valuation Dynamics - In the first three quarters of 2025, the pharmaceutical sector experienced a notable divergence in performance across sub-sectors, with innovative drugs and CXO showing signs of recovery while others lagged [3][15] - The total revenue for 461 A-share listed companies in the pharmaceutical sector is projected to reach CNY 24,640 billion in 2024, with a slight decline of 0.7% year-on-year [15][18] - The overall valuation of the pharmaceutical sector remains low compared to historical averages, with innovative drugs benefiting from expectations of business development (BD) transactions [3][4][15] Innovative Drugs - The report emphasizes that the rapid development and lower costs of new drug development in China have positioned the country as a global leader, contributing approximately one-third of the global innovative R&D pipeline in 2025 [4][14] - The introduction of the commercial insurance innovative drug directory in 2025 is expected to stimulate payment growth for innovative drug products [3][4] CXO Sector - The CXO market is witnessing improved supply and demand dynamics, with CDMO companies entering a high-growth cycle due to strong demand for new molecular entities [4][15] - Key players in the CDMO space, such as WuXi AppTec, are highlighted for their robust project pipelines and market positioning [4][15] Life Sciences Upstream - The recovery in downstream demand is driving revenue growth in the life sciences sector, with companies actively pursuing mergers and acquisitions to expand their market presence [4][15] - Companies like Bide Pharmaceutical and Haoyuan Pharmaceutical are noted for their strong cash reserves and strategic acquisition activities [4][15] AI in Healthcare - The report discusses the impact of AI in healthcare, driven by government policies and the development of large-scale AI models, with companies like JD Health and Yimaitong being key players [4][5] High-End Medical Equipment - The high-end medical equipment sector is expected to benefit from a recovery in domestic procurement, import substitution, and accelerated international expansion [4][5] - Companies such as United Imaging and Kaili Medical are identified as potential beneficiaries of these trends [4][5] Orthopedic Consumables - The orthopedic market is expanding due to an aging population, with the negative impacts of centralized procurement clearing up, leading to a resurgence in demand for robotic-assisted surgeries [4][5] Traditional Chinese Medicine - Some traditional Chinese medicine companies are showing signs of revenue and profit improvement, driven by seasonal demand and adjustments in the essential medicine directory [4][5]

Investment Rating - The investment rating for the pharmaceutical and biotechnology industry is "Positive" [2]. Core Viewpoints - The recent performance of the pharmaceutical sector has been sluggish, with the innovative drug sector experiencing a significant rise in expectations earlier this year, now undergoing a correction. However, innovative medical devices are expected to benefit from ongoing government support for medical equipment upgrades and accelerated domestic replacement of high-end medical devices, alongside continuous expansion into overseas markets. A recovery is anticipated starting in Q3 2025, with performance gradually improving in 2026 [3][9]. - The high-end medical device sector is driven by the recovery of in-hospital procurement, suggesting a focus on companies such as United Imaging, Shandong Weigao, and Mindray Medical. The demand for consumer medical devices is gradually recovering, with a shift in market share from imported brands, indicating potential in companies like Kefu Medical and Yuyue Medical. The orthopedic consumables market has reached a price floor, with opportunities for market share growth in orthopedic robotics and overseas expansion, highlighting companies like Aikang Medical and Chuangli Medical [3][9]. - The pharmaceutical equipment sector is undergoing a cyclical recovery, with rapid overseas growth opening new avenues for growth. Domestic margins are expected to stabilize and profitability to improve, with a return to rational competition anticipated from late 2024. The recovery in innovative drug financing and frequent business development transactions are expected to drive a revival in contract manufacturing organizations (CMOs), positively impacting the pharmaceutical equipment industry. Additionally, global strategic safety backups and commitments from multinational pharmaceutical companies to invest in the U.S. market are projected to accelerate fixed asset expenditures in the pharmaceutical sector over the next three years, with a focus on companies like Senson International and Dongfulong [3][9]. - In the CXO and upstream life sciences supply chain, leading global CXO companies such as WuXi AppTec and Kanglong Huacheng are highlighted. Domestic clinical CRO leaders like Tigermed and Pruce are also recommended, along with resource-based CXOs such as Zhaoyan New Drug and Mediso. The upstream life sciences supply chain includes companies like Baipusais and Haier Biomedical [3][9]. Summary by Sections Market Performance - The pharmaceutical and biotechnology sector's return was -1.04% last week, ranking 17th among 31 sub-industry indices. The medical services sub-sector had the highest weekly return at 1.67%, while the pharmaceutical commercial sub-sector had a return of -4.26% [3][9]. Industry Trends - The report emphasizes the ongoing low performance of the pharmaceutical sector, particularly in innovative drugs, while highlighting the potential recovery in innovative medical devices and the pharmaceutical equipment sector [3][9]. Recommendations - Specific companies to watch include United Imaging, Mindray Medical, Kefu Medical, and Aikang Medical in the high-end medical device sector, as well as Senson International and WuXi AppTec in the pharmaceutical equipment and CXO sectors [3][9].